Varenicline Uses, Dosage, Side Effects & Price | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Varenicline
Therapeutic Class: Smoking Cessation Aid
Subclass: Partial Nicotinic Acetylcholine Receptor Agonist
Speciality: Psychiatry
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
- Tablet: 0.5 mg
- Tablet: 1 mg
- Starter Pack: 0.5 mg × 11 tablets + 1 mg × 14 tablets (available with some brands)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ Tobacco Dependence — Smoking Cessation in Adults
Dosing Protocol (12-week course)
| Phase | Days | Dose | Instructions |
|
Week 1 (Titration)
|
Day 1–3 | 0.5 mg once daily | Patient continues smoking; set quit date for Day 8–14 |
| Day 4–7 | 0.5 mg twice daily | Continue smoking until quit date | |
|
Weeks 2–12 (Maintenance)
|
Day 8 onwards | 1 mg twice daily | Target quit date; continue for 11 weeks |
Structured Dose Summary:
| Parameter | Recommendation |
|
Starting dose
|
0.5 mg once daily (Days 1–3) |
|
Titration
|
0.5 mg twice daily (Days 4–7), then 1 mg twice daily from Day 8 |
|
Usual maintenance dose
|
1 mg twice daily |
|
Maximum dose
|
1 mg twice daily (2 mg/day total) |
Clinical Notes:
- Set target quit date within Days 8–35 of starting therapy (flexible approach)
- Total treatment duration: 12 weeks
- For sustained abstinence: may extend additional 12 weeks (total 24 weeks) in those who successfully quit
- Combine with behavioural counselling for improved outcomes
- Take with food and full glass of water to reduce nausea
- No tapering required when discontinuing
Alternative Flexible Quit Approach:
For patients not ready for fixed quit date:
- Start varenicline as above
- Reduce smoking during first 12 weeks
- Quit by Week 12
- Continue additional 12 weeks post-quit (total 24 weeks)
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Notes |
|
Smokeless Tobacco Cessation (gutka, khaini, paan with tobacco)
|
Standard 12-week regimen as above | 12 weeks; may extend to 24 weeks | OFF-LABEL; Specialist only; Evidence: Limited Indian studies; efficacy less robust than for cigarette smoking; AIIMS Tobacco Cessation Clinic experience |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable — Varenicline is NOT approved for use in patients below 18 years of age.
Secondary Indications — Paediatrics (Off-label, if any)
Not applicable — No established off-label paediatric indications.
Age Restriction Statement:
- Not recommended below 18 years of age
- Safety and efficacy not established in paediatric population
- No Indian data available for adolescent tobacco users
- Use only in research settings with appropriate ethical oversight
RENAL ADJUSTMENT
| eGFR (mL/min/1.73m²) | Dosing Recommendation |
|
≥30
|
No adjustment required |
|
<30 (not on dialysis)
|
Starting dose: 0.5 mg once daily; Maximum dose: 0.5 mg twice daily based on tolerability |
|
End-stage renal disease on haemodialysis
|
0.5 mg once daily; Maximum: 0.5 mg once daily; Administer after dialysis session |
Notes:
- Varenicline is primarily renally excreted (>90% unchanged)
- Monitor closely for increased neuropsychiatric and gastrointestinal adverse effects in renal impairment
- Peritoneal dialysis: Limited data; use as for eGFR <30
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|
Mild impairment
|
No dose adjustment required |
|
Moderate impairment
|
No dose adjustment required |
|
Severe impairment
|
Limited data; no specific adjustment recommended but use with caution; specialist supervision advised |
Note: Varenicline undergoes minimal hepatic metabolism; primarily excreted unchanged via kidneys.
CONTRAINDICATIONS
- Known hypersensitivity to varenicline or any excipient
- History of serious hypersensitivity reactions (angioedema, Stevens-Johnson syndrome) to varenicline
- Prior serious neuropsychiatric reaction attributable to varenicline requiring discontinuation
CAUTIONS
- History of psychiatric illness (depression, bipolar disorder, schizophrenia, anxiety disorders)
- History of suicidal ideation or suicide attempt
- History of seizures or conditions lowering seizure threshold
- Pre-existing cardiovascular disease (conflicting evidence regarding CV risk; monitor closely)
- Renal impairment (dose adjustment required)
- Concurrent use of alcohol (enhanced neuropsychiatric effects)
- Patients operating heavy machinery or driving (somnolence, dizziness may occur)
- Elderly patients with reduced renal function
PREGNANCY
| Parameter | Recommendation |
|
Risk Category
|
Category C — Insufficient human data; use only if benefit outweighs risk |
|
Safety Data
|
Limited human data; animal studies inconclusive |
|
Preferred Alternatives
|
Nicotine Replacement Therapy (NRT) patches/gum preferred in Indian obstetric practice; behavioural counselling first-line |
|
When May Be Used
|
Only if NRT ineffective/contraindicated and benefit clearly outweighs risk; specialist input mandatory |
|
Monitoring
|
Fetal growth (ultrasound); maternal mental health status |
LACTATION
| Parameter | Recommendation |
|
Compatibility
|
Unknown; use with caution; avoid if possible |
|
Expected Levels in Milk
|
Unknown; likely low due to high renal excretion |
|
Preferred Alternatives
|
Behavioural counselling; NRT (gum, patch) preferred |
|
Infant Monitoring
|
Irritability, feeding difficulty, sedation, weight gain if maternal use unavoidable |
ELDERLY
| Parameter | Recommendation |
|
Starting Dose
|
Standard adult titration schedule |
|
Titration
|
May consider slower titration if tolerability concerns |
|
Extra Risks
|
Reduced renal function (dose adjust per eGFR); increased sensitivity to CNS effects; confusion; falls risk; nausea more pronounced |
|
Monitoring
|
Renal function; neuropsychiatric symptoms; tolerability |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Alcohol
|
Enhanced neuropsychiatric effects including aggression, amnesia, reduced alcohol tolerance | Advise caution; counsel patients to reduce/avoid alcohol during treatment |
|
Cimetidine
|
Reduced renal clearance of varenicline; increased plasma levels by ~29% | Monitor for increased adverse effects; consider dose reduction in renal impairment |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Nicotine Replacement Therapy (NRT)
|
Increased incidence of nausea, headache, dizziness, fatigue when combined | Combination may be considered in specialist settings; monitor tolerability closely |
|
Insulin, oral hypoglycaemics
|
Smoking cessation alters insulin sensitivity; may require dose adjustment of diabetes medications | Monitor blood glucose closely; reduce diabetes medication doses as needed post-quit |
|
Warfarin
|
Smoking cessation affects CYP1A2 activity; warfarin metabolism may decrease | Monitor INR closely after quit date; warfarin dose reduction may be needed |
|
Theophylline
|
Smoking cessation reduces CYP1A2 induction; theophylline levels may increase | Monitor theophylline levels; dose reduction likely required post-quit |
|
Clozapine
|
Smoking cessation increases clozapine levels (CYP1A2 substrate) | Reduce clozapine dose by 30–50% upon quitting; monitor closely |
Note: Many drug interactions are due to effects of smoking cessation itself, not varenicline pharmacokinetically.
COMMON ADVERSE EFFECTS
- Nausea (most common; up to 30%; dose-dependent)
- Insomnia
- Abnormal/vivid dreams
- Headache
- Flatulence, constipation
- Dry mouth
- Dysgeusia (taste disturbance)
- Increased appetite
- Fatigue, somnolence
SERIOUS ADVERSE EFFECTS
- Neuropsychiatric events: Depression, agitation, suicidal ideation/behaviour, hostility, psychosis — Discontinue immediately if emergent; refer to psychiatry
- Seizures — Especially in predisposed patients; discontinue
- Angioedema — Discontinue immediately; provide emergency care
- Stevens-Johnson Syndrome/Erythema multiforme — Rare; discontinue immediately
- Myocardial infarction — Increased risk reported in some studies; caution in cardiovascular disease patients
- New or worsening cardiovascular events — Monitor in high-risk patients
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Renal function (serum creatinine, eGFR); psychiatric history assessment (depression, suicidal ideation, anxiety, psychosis); cardiovascular risk assessment |
|
After initiation (Weeks 1–4)
|
Monitor mood, behaviour changes, suicidal thoughts; tolerability (especially nausea); sleep quality |
|
During treatment
|
Assess abstinence status at each visit; neuropsychiatric symptoms; cardiovascular symptoms in high-risk patients |
|
Long-term/Follow-up
|
Abstinence maintenance; relapse assessment; weight monitoring |
BRANDS AVAILABLE IN INDIA
- Champix® (Pfizer) — Most widely recognised
- Varenismart®
- Varnitrip®
- Vareniclin®
Note: Availability may be limited in some regions; verify local supply before prescribing.
PRICE RANGE (INR)
| Formulation | Approximate Price |
| 0.5 mg tablet | ₹25–40 per tablet |
| 1 mg tablet | ₹45–70 per tablet |
| Starter pack (complete) | ₹1,500–2,500 per pack |
| Full 12-week course | ₹8,000–12,000 approximately |
- Not included in NLEM 2022
- Not under NPPA price control
- Cost may be barrier in public sector/low-resource settings
- Limited availability in government hospitals
CLINICAL PEARLS
- Nausea management: Most common reason for discontinuation; advise taking with food and full glass of water; starting with lower dose and titrating helps tolerance
- Quit date flexibility: Setting quit date between Days 8–35 provides flexibility; gradual reduction approach may suit some patients
- Combination therapy: Varenicline + NRT may be considered in heavily dependent smokers under specialist supervision; monitor for increased adverse effects
- Psychiatric monitoring essential: Screen for psychiatric history at baseline; counsel patients and families to report mood/behaviour changes immediately
- Duration matters: 12-week course is standard; extending to 24 weeks improves long-term abstinence in successful quitters
- Not just for cigarettes: May be tried for smokeless tobacco users (gutka, khaini) though evidence is limited; behavioural support critical in these cases
TAGS
varenicline; smoking cessation; tobacco dependence; nicotine addiction; Champix; psychiatric-caution; renal-dose-adjust; nausea; behavioural therapy; specialist-monitoring
VERSION
RxIndia v0.2 — 03 Feb 2026
REFERENCES
- CDSCO approved prescribing information
- Indian Pharmacopoeia / NFI
- API Textbook of Medicine
- ICMR Guidelines on Tobacco Cessation (2021)
- AIIMS Tobacco Cessation Clinic protocols
- Indian Psychiatric Society consensus on pharmacotherapy for tobacco dependence
- Goodman & Gilman’s: The Pharmacological Basis of Therapeutics
- International RCTs/meta-analyses (for combination therapy and smokeless tobacco — off-label indications only)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.